Mostrando 1 - 20 Resultados de 24 Para Buscar '"Kreuzberg"', tiempo de consulta: 0.27s Limitar resultados
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
    por Steeb, Theresa, Wessely, Anja, Alter, Mareike, Bayerl, Christiane, Bender, Armin, Bruning, Guido, Dabrowski, Evelyn, Debus, Dirk, Devereux, Nina, Dippel, Edgar, Drexler, Konstantin, Dücker, Pia, Dummer, Reinhard, Emmert, Steffen, Elsner, Peter, Enk, Alexander, Gebhardt, Christoffer, Gesierich, Anja, Goebeler, Matthias, Goerdt, Sergij, Goetze, Steven, Gutzmer, Ralf, Haferkamp, Sebastian, Hansel, Gesina, Hassel, Jessica C., Heinzerling, Lucie, Kähler, Katharina C., Kaume, Kjell M., Krapf, Wolfgang, Kreuzberg, Nicole, Lehmann, Percy, Livingstone, Elisabeth, Löffler, Harald, Loquai, Carmen, Mauch, Cornelia, Mangana, Johanna, Meier, Friedegund, Meissner, Markus, Moritz, Rose K. C., Maul, Lara Valeska, Müller, Verena, Mohr, Peter, Navarini, Alexander, Van Nguyen, Ahn, Pfeiffer, Christiane, Pföhler, Claudia, Posch, Christian, Richtig, Erika, Rompel, Rainer, Sachse, Michael M., Sauder, Stefanie, Schadendorf, Dirk, Schatton, Kerstin, Schulze, Hans-Joachim, Schultz, Erwin, Schilling, Bastian, Schmuth, Matthias, Simon, Jan. C., Streit, Markus, Terheyden, Patrick, Thiem, Alexander, Tüting, Thomas, Welzel, Julia, Weyandt, Gerhard, Wesselmann, Ulrich, Wollina, Uwe, Ziemer, Mirjana, Zimmer, Lisa, Zutt, Markus, Berking, Carola, Schlaak, Max, Heppt, Markus V.
    Publicado 2020
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 15
    “…Independent risk factors for 3GCREB colonization were prior colonization / infection with MDRO (OR 2.30, 95% CI 1.59–3.32), prior antimicrobial treatment (OR 1.97, 95% CI 1.59–2.45), male sex (OR 1.38, 95% CI 1.12–1.70), prior travelling outside Europe (OR 2.39, 95% CI 1.77–3.22) and places of residence in the Berlin districts Charlottenburg-Wilmersdorf (OR 1.52, 95% CI 1.06–2.18), Friedrichshain-Kreuzberg (OR 2.32, 95% CI 1.44–3.74) and Mitte (OR 1.73, 95% CI 1.26–2.36). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 16
  17. 17
  18. 18
  19. 19
    “…BACKGROUND: The clinical benefit of anti-spike mAbs for prophylaxis and treatment of SARS-CoV-2 is now well established (Baum 2020, Loo 2022, Westendorf 2022, Jones 2021, Kreuzberger 2021, Cathcart 2021, Hirsch 2022, Shi 2020); However, the evolution of SARS CoV-2 due to immune pressure has compromised the utility of all previously approved mAbs which target the variable, immune dominant receptor binding domain of the Spike protein. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  20. 20
Herramientas de búsqueda: RSS